文献速递胸部肿瘤

EGFR突变亚型与非小细胞肺癌免疫检查点阻断治疗的应答

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.
PubMed 文献 · Ann Oncol · 2019-01-01

本研究回顾性分析了171例接受免疫检查点抑制剂治疗的EGFR突变肺癌患者的临床与分子数据,并与212例EGFR野生型肺癌比较。结果显示,EGFR外显子19改变(EGFRΔ19)患者接受PD-(L)1阻断的结局较野生型更差,而EGFRL858R肿瘤与野生型相似;EGFRT790M状态和PD-L1表达不影响应答或生存。

要点

  • EGFRΔ19肺癌患者PD-(L)1阻断结局较EGFR野生型差,EGFRL858R肿瘤则与野生型相似。
  • EGFRT790M状态和PD-L1表达未影响免疫检查点阻断的应答或生存结局。
  • PD-L1表达在各EGFR等位基因间相似;EGFRΔ19肿瘤突变负荷低于EGFRL858R。

核心结论

  • EGFR突变肿瘤对免疫检查点抑制剂总体应答率低,但结局因等位基因而异;理解EGFR突变肿瘤的异质性可能有助于确定PD-(L)1治疗在该病中的获益与用途。

研究设计与样本

  • 回顾性分析171例接受免疫检查点抑制剂治疗的EGFR突变肺癌患者来自耶鲁癌症中心、纪念斯隆凯特琳癌症中心、加州大学洛杉矶分校和丹娜法伯癌症研究所的去标识临床与分子数据。
  • 另纳入383例有测序数据的EGFR突变肺癌病例(来自耶鲁癌症中心、纪念斯隆凯特琳癌症中心和癌症基因组图谱),用于评估肿瘤突变负荷与特定EGFR改变的关系。

主要发现

  • 与212例EGFR野生型肺癌相比,携带EGFR外显子19改变(EGFRΔ19)的肺肿瘤患者接受PD-(L)1阻断的结局更差,而EGFRL858R肺肿瘤则相似。
  • EGFRT790M状态和PD-L1表达未影响免疫检查点阻断的应答或生存结局。
  • PD-L1表达在各EGFR等位基因间相似。
  • 尽管吸烟史相似,EGFRΔ19改变的肺肿瘤突变负荷低于EGFRL858R肺肿瘤。

临床怎么用

  • 作者认为,理解EGFR突变肿瘤的异质性可能有助于确定PD-(L)1治疗在该病中的获益与用途。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although EGFR mutant tumors exhibit low response rates to immune checkpoint blockade overall, some EGFR mutant tumors do respond to these therapies; however, there is a lack of understanding of the characteristics of EGFR mutant lung tumors responsive to immune checkpoint blockade. PATIENTS AND METHODS: We retrospectively analyzed de-identified clinical and molecular data on 171 cases of EGFR mutant lung tumors treated with immune checkpoint inhibitors from the Yale Cancer Center, Memorial Sloan Kettering Cancer Center, University of California Los Angeles, and Dana Farber Cancer Institute. A separate cohort of 383 EGFR mutant lung cancer cases with sequencing data available from the Yale Cancer Center, Memorial Sloan Kettering Cancer Center, and The Cancer Genome Atlas was compiled to assess the relationship between tumor mutation burden and specific EGFR alterations. RESULTS: Compared with 212 EGFR wild-type lung cancers, outcomes with programmed cell death 1 or programmed death-ligand 1 (PD-(L)1) blockade were worse in patients with lung tumors harboring alterations in exon 19 of EGFR (EGFRΔ19) but similar for EGFRL858R lung tumors. EGFRT790M status and PD-L1 expression did not impact response or survival outcomes to immune checkpoint blockade. PD-L1 expression was similar across EGFR alleles. Lung tumors with EGFRΔ19 alterations harbored a lower tumor mutation burden compared with EGFRL858R lung tumors despite similar smoking history. CONCLUSIONS: EGFR mutant tumors have generally low response to immune checkpoint inhibitors, but outcomes vary by allele. Understanding the heterogeneity of EGFR mutant tumors may be informative for establishing the benefits and uses of PD-(L)1 therapies for patients with this disease.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Hastings K, Yu HA, Wei W, et al. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. Ann Oncol. 2019. PMID: 31086949. doi:10.1093/annonc/mdz141

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。